EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy

Emily Chan, Stephanie L Pugh, Jeffry P Simko, Felix Feng, William U Shipley, Himanshu R Lukka, Jean-Paul Bahary, Thomas M Pisansky, Kenneth Lee Zeitzer, Elizabeth Gore iD, Jason A Efstathiou, Seth A Rosenthal und 8 weitere

The Prostate · 2025

DOI: 10.1002/pros.70018 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Prostate, 2025. Verfasst von Emily Chan und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Salvage Therapy, Lymph Nodes. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, This project was supported by grants UG1CA189867 (NCORP), U10CA180868 (NRG Oncology Operations), U24CA196067 (NRG Specimen Bank) from the National Cancer Insti….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aim to evaluate whether increased lymph node yield at prostatectomy (RP) is associated with improved outcomes in NRG/RTOG 9601, a randomized clinical trial of men who underwent either radiation (RT) alone or RT + bicalutamide for PSA elevation following RP for pT2/T3 prostate cancer.

Methods

We reviewed available pathology reports for patients in NRG/RTOG 9601 to determine the nodal count at RP. Cox proportional hazards models were used to assess effect of lymph nodes yield, arm (RT alone or RT + bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease‐specific survival.

Results

Of 760 patients, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range: 0–33, IQR: 3–9). There were no significant differences between arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm. There was no significant association between total lymph nodes and overall or disease‐specific survival with both arms combined and when adjusting for arm. Notably, interaction analysis revealed that in seminal vesicle invasion, there was a significant association between lymph node yield and OS and DSS (HR = 0.91, 95% CI: 0.83–0.99, p = 0.034; HR = 0.87, 95% CI: 0.77–0.99, p = 0.029, respectively).

Conclusions

Although lymph node yield in NRG/RTOG 9601 did not show association with adverse outcomes in the entire cohort or either arm alone, there was significant association between lymph node yield and adverse outcomes when seminal vesicle invasion was present. The therapeutic benefit of extensive lymph node dissection remains uncertain but could be more relevant in higher risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomySalvage TherapyLymph NodesMaleHumansMiddle AgedAgedPrognosisTosyl CompoundsLymph Node ExcisionLymphatic MetastasisNitrilesAnilidesAndrogen Antagonists

Stichwörter der Autor:innen

lymph nodepelvic lymph node dissectionprognosisprostate cancerprostatectomyradiotherapy

Substanzen

Tosyl CompoundsbicalutamideNitrilesAnilidesAndrogen Antagonists

Autor:innen und Institutionen

  • University of San Francisco, San Francisco, California, USA.
  • Stanford University, Stanford, California, USA.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada.
  • Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.

ORCID-Profile: Elizabeth Gore, Robert T Dess

Förderung

  • NCI NIH HHS
  • This project was supported by grants UG1CA189867 (NCORP), U10CA180868 (NRG Oncology Operations), U24CA196067 (NRG Specimen Bank) from the National Cancer Insti…

Zitieren

APA

Chan, E., Pugh, S. L., Simko, J. P., Feng, F., Shipley, W. U., Lukka, H. R., Bahary, J. P., Pisansky, T. M., Zeitzer, K. L., Gore, E., Efstathiou, J. A., Rosenthal, S. A., Balogh, A. G., Lovett, R. D., Wong, A., Dess, R. T., McGinnis, L. S., Kuettel, M., DeMora, L., & Sandler, H. M. (2025). Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy. The Prostate. https://doi.org/10.1002/pros.70018

Vancouver

Chan E, Pugh SL, Simko JP, Feng F, Shipley WU, Lukka HR, et al. Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy. The Prostate. 2025. doi:10.1002/pros.70018

BibTeX
@article{Chan2025,
  author = {Chan, Emily and Pugh, Stephanie L and Simko, Jeffry P and Feng, Felix and Shipley, William U and Lukka, Himanshu R and Bahary, Jean-Paul and Pisansky, Thomas M and Zeitzer, Kenneth Lee and Gore, Elizabeth and Efstathiou, Jason A and Rosenthal, Seth A and Balogh, Alexander G and Lovett, Richard D and Wong, Anthony and Dess, Robert T and McGinnis, L Scott and Kuettel, Michael and DeMora, Luda and Sandler, Howard M},
  title = {Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.70018}
}
Kostenlos starten →